30 closest matches · ranked by relevance
G6PD Deficiency
Primary: Sensitivity of SD Biosensor POC G6PD Test for Identifying G6PD Deficient Individuals — 100.0; 100.0 percentage of participants
G6PD Deficiency
Primary: Sensitivity of SD Biosensor STANDARD G6PD Test for Identifying G6PD Deficient Individuals — 100.0; 100.0 percentage of participants
G6PD Deficiency
Primary: Sensitivity of SD Biosensor STANDARD G6PD Test for Identifying G6PD Deficient Individuals — 100.0; 100.0 percentage of participants
Diabetes · Obesity
Primary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05
Malaria
Primary: The Proportion of Adverse and Serious Adverse Events Following Unsupervised Primaquine Treatment — 0; 0; 0 events
Glucose Transporter Type 1 Deficiency Syndrome · GLUT1 Deficiency Syndrome
Primary: Number of Participants With Reduction in Spike-wave Fraction of the EEG Recording Time — 13 Participants
GLUT1DS1 · Epilepsy · Glut1 Deficiency Syndrome 1, Autosomal Recessive
Primary: Neuropsychological Score of Sustained Attention — 11 Participants
Pyruvate Kinase Deficiency
Primary: Percentage of Participants Experiencing at Least One Adverse Event (AEs) in the Core Period — 96.3; 100.0 percentage of participants
Diabetes Mellitus, Type 1
Primary: Glutathione Concentration — 541; 551 umol/L
Malaria, Vivax
Primary: Percentage of Participants With Clinically Relevant Hemolysis. — 2.41; 1.18 Percentage of participants
Pompe Disease
Primary: Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. — 40,031; 29,638; 5,509,882; 1,907,161 mU/mL
Diabetes Mellitus, Type 1
Primary: Glutathione Concentration — 706; 734 umol/L
GTP Cyclohydrolase Deficiency
Primary: Change in BH4 Levels in Cerebral Spinal Fluid — 6; 10.7; 5.3; 13.2 nmol/L
Pompe Disease · Glycogen Storage Disease Type II (GSD-II) · Acid Maltase Deficiency Disease
Primary: Recumbent Height/Length of Participants in Centimeters (cm) — 80.4; 93.8; 67.7; 91.1 cm
Pyruvate Kinase Deficiency · Anemia, Hemolytic
Primary: Percentage of Participants Achieving a Hemoglobin (Hb) Response (HR) — 0; 40.0 percentage of participants — p=<0.0001
Pompe Disease · Glycogen Storage Disease Type II (GSD-II) · Glycogenesis 2 Acid Maltase Deficiency
Primary: Participants' Efficacy Response During the Treatment Period as Compared to Baseline for Participants With Respiratory Decline on Standard Treatment — 0; 0; 0; 1…
Gaucher Disease, Type 1
Primary: Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group. — 2.429 g/dL — p=<0.0001
Diabetes Mellitus, Type 1
Primary: Change in Plasma Glucose — 81.4; 84.2; 54.0 mg/dL — p=<0.001
Healthy Volunteers
Primary: Serious Ophthalmic Safety Event — 45; 48 Participants
Sickle Cell Anemia · Thalassemia
Primary: Number of Occurrences of Painful Sickle Cell Crises — 4.5; 10.8 Crisis — p=0.076
HIV Infection · Erythrocyte Glutathione Deficiency
Primary: Muscle Glutathione Concentration — 0.5; 2.2 micromol/g.Hb
Pyruvate Kinase Deficiency
Primary: All Cohorts: Number of Participants With at Least One Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or…
Hypoglycemia
Primary: Serious Adverse Events — 0; 0; 0 events
Type 1 Diabetes Mellitus
Primary: Change in Brachial Artery Diameter — -0.93 percentage of dilation
Diabetes, Gestational
Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14
Pulmonary Hypertension · Sickle Cell Disease · Thalassemia
Primary: Erythrocyte Glutamine/Glutamate Ratio at 8 Weeks — 2.40 Ratio
Congenital Hyperinsulinism
Primary: Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind) — 2; 0 Participants
Gestational Diabetes · Eye Diseases · Retinal Disease
Primary: Glucose Levels of the Groups in Pregnant Women With Impaired Blood Sugar and/or Gestational DM — 111.67; 154; 83.06; 88.15 mg/dl
Arginase 1 Deficiency
Primary: Change From Baseline in Plasma Arginine Concentrations in Subjects <24 Months of Age With Arginase 1 Deficiency (ARG1-D). — -221.53 μM
Pyruvate Kinase Deficiency · Anemia, Hemolytic
Primary: Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 2 — 37 percentage of participants — p=0.0002